That's because the broker recently named all three ASX 200 shares as buys. Here's what you need to know:

Magellan Financial Group Ltd (ASX: MFG)

This fund manager could be worth considering according to the broker. It believes the merger with Barrenjoey is a game-changer and provides "additional pathways for growth."

Morgans has put a buy rating and $11.99 price target on Magellan's shares. It said:

MFG has given an end-to-March 2026 quarterly FUM update. FUM (A$37.5bn) was down 6% for the quarter due to a combination of outflows across most funds and market movements. Overall this was a softer quarter at the headline level, albeit some impacts from market volatility are unsurprising. We downgrade our MFG FY26F/FY27F EPS by -1%/-8% due to slightly weaker FUM assumptions and also applying more conservatism to our future Barrenjoey earnings forecasts.

Our PT falls to A$11.99 (from A$12.43). Whilst MFG's Investment Management performance remains patchy, we think the Barrenjoey merger fundamentally changes MFG's overall outlook, strengthening the business and providing additional pathways for growth. MFG also retains a strong balance sheet (~A$650m of liquidity, post deal). BUY maintained.

Nufarm Ltd (ASX: NUF)

Another ASX 200 share that has been given the thumbs up is agricultural chemicals company Nufarm.

In response to a better-than-expected performance in FY 2026, the broker put a buy rating and $4.05 price target on its shares. It said:

Pleasingly, NUF's 1H26 EBITDA guidance was slightly higher than expected and it has had a strong 1H. Importantly, its leverage guidance is materially better than expected. Initial outlook comments for the 2H26 were positive and a new A$50m cost out program has been announced.

Given the appreciation in active ingredient and fish oil prices, NUF's previous FY26 guidance could prove to be conservative. NUF is our key pick of the ag and chemical sector. The company is materially undervalued and we reiterate our BUY rating with a new price target of A$4.05.

Sigma Healthcare Ltd (ASX: SIG)

Morgans is also bullish on Chemist Warehouse owner Sigma Healthcare.

Due to its strong growth outlook and recent share price weakness, the broker has put a buy rating and $3.36 price target on the ASX 200 share. It explains:

SIG is a leading healthcare wholesaler, distributor and retail pharmacy franchisor with operations in Australia, NZ, Ireland and the UAE. We are forecasting ~20% EBIT growth p.a. over the next few years driven by strong LFL sales growth, store rollout (domestically and internationally), operating efficiencies and $100m p.a. synergies by FY29. Given the share price weakness, we have upgraded our recommendation to BUY (from ACCUMULATE) with an unchanged target price of $3.36 and 26% upside.

The post Morgans names 3 ASX 200 shares to buy now appeared first on The Motley Fool Australia.

Compounding is powerful because it means the numbers can deliver growth on growth as the years go by. After several years, the business could be generating dramatically bigger revenue and earnings.

The two ASX share below have significant growth plans, and I'm excited by what they could achieve.

L1 Group Ltd (ASX: L1G)

L1 Group describes itself as an alternative investment manager that is "committed to providing best-in-class investment products that deliver exceptional risk-adjusted returns" for investors.

Two of its most well-known investment products are listed investment companies (LICs) which provide L1 Group with locked-in funds under management (FUM). Those LICs are L1 Long Short Fund Ltd (ASX: LSF) and L1 Global Long Short Fund Ltd (ASX: GLS).

I'm expecting the ASX share to generate revenue growth due to attracting new FUM into existing strategies, launching new funds and delivering investment growth with its existing funds.

Fund managers can be very scalable because it doesn't take 10% more staff and a 10% bigger office to manage 10% more FUM. Therefore, I'm expecting profit margins to increase.

L1 notes that its client base is extremely diversified, with 91% of revenue coming from non-institutional clients, which I think makes it less vulnerable if short-term fund performance were disappointing.

The fund manager has also talked about launching joint ventures and acquiring existing investment managers, which add further growth potential.

According to the projection on Commsec, the L1 Group share price is valued at 20x FY27's estimated earnings.

Sigma Healthcare Ltd (ASX: SIG)

Sigma is best known as the owner of pharmacy giant Chemist Warehouse, which is growing rapidly and has international ambitions.

In the FY26 first-half, Australian Chemist Warehouse-branded store sales grew 17.2%, with like-for-like sales growth of 15%. This shows that the business is delivering excellent levels of organic growth considering it's a physical store retailer.

Chemist Warehouse is growing its own brands (including Wagner) and expanding its Australian store network, which are pleasing tailwinds for the business in its core markets, which could help it deliver profit improvement for many years ahead.

Internationally, the ASX share is expanding in New Zealand and Ireland at a fast pace. In the first half of FY26, it opened 12 new stores and expects to open another 11 in the second half of FY26. In HY26, Ireland sales rose 49.6% and New Zealand sales increased 22.4%.

I'm not sure what its local and global store network will look like in 10 years from now, but I'm optimistic it will be significantly larger.

According to the projection on Commsec, the Sigma share price is valued at 33x FY28's estimated earnings.

The post 2 top ASX shares to buy and hold for the next decade appeared first on The Motley Fool Australia.

That usually leads me toward companies that are building platforms, scaling globally, or reshaping their industries.

Here are three ASX 200 shares that stand out to me right now.

Xero Ltd (ASX: XRO)

Xero is evolving into something much bigger than accounting software.

At its core, it sits on top of financial data for millions of small businesses. That position creates a powerful foundation for expanding into adjacent services and delivering more value over time.

What I find particularly interesting right now is how the company is leaning into artificial intelligence (AI).

According to its recent investor briefing, Xero sees the long-term opportunity expanding its total addressable market by around four times as AI capabilities are layered into its platform.

That shift changes how I think about the business. It moves beyond subscription accounting software and toward a broader system that helps businesses make decisions, automate processes, and improve performance.

On top of that, the integration with Melio is opening up a large US payments opportunity, which adds another growth driver.

I think Xero is building a platform that can continue to expand its reach and relevance over time.

Hub24 Ltd (ASX: HUB)

HUB24 is benefiting from structural change within the wealth industry.

More advisers are moving toward platform-based solutions, and HUB24 continues to capture that shift.

What stands out is the pace at which the business is scaling. In its latest results, platform funds under administration reached $152.3 billion, supported by record net inflows of $10.7 billion in the half.

That growth reflects strong demand from advisers and ongoing market share gains.

But it isn't settling for that. HUB24 continues to invest in new solutions, including an emerging ecosystem that leverages AI and integrated tools to improve adviser productivity.

For me, this is a business where growth is driven by both industry tailwinds and continued innovation within its platform.

Sigma Healthcare Ltd (ASX: SIG)

Sigma Healthcare is another ASX 200 share I think could be a best buy. It is shaping into a very different business following its merger with Chemist Warehouse.

It now combines wholesale distribution with a large and growing retail network, which creates a broader and more scalable model.

The recent first-half results highlight how that combination is performing. Revenue increased 15% to $5.5 billion, with strong growth across both domestic and international markets, supported by expanding store networks and increasing demand.

What I find attractive is the runway ahead. The company continues to open new stores, expand its private label offering, and drive efficiencies through scale. 

Overall, I think Sigma is transitioning into an integrated healthcare platform with multiple ways to grow.

Foolish takeaway

What stands out to me is how each of these businesses is expanding its opportunity set.

Xero is building a broader platform around financial data and AI, Hub24 is scaling alongside structural growth in platform-based investing, and Sigma Healthcare is strengthening its position across retail and distribution.

That ongoing expansion is what I look for when identifying high-quality ASX 200 shares to buy now.

The post I think these are some of the best ASX 200 shares to buy now appeared first on The Motley Fool Australia.

Here are four ASX 200 shares I think offer these qualities, and I would be looking at today.

Hub24 Ltd (ASX: HUB)

Hub24 is a business that benefits from momentum. Not the kind you see in share price charts, but the kind that builds within an industry over time. Once a financial adviser adopts an investment and superannuation platform, integrates it into their workflow, and brings clients onto it, that decision tends to stick.

What I like is how that creates a layering effect. New clients are added, existing clients grow their portfolios, and over time, the platform becomes more deeply embedded in the advice process. Growth does not rely on a single catalyst; it builds gradually as the ecosystem expands.

For me, it is a business where scale can quietly do a lot of the work over the long term.

REA Group Ltd (ASX: REA)

REA Group is one of those ASX 200 shares where the product is almost unavoidable.

Anyone who has searched for property in Australia has likely interacted with its platform, and that kind of reach creates a strong position in the market.

What I like in particular is how pricing power shows up. Agents are not just paying for a listing; they are paying for visibility in a highly competitive environment. When demand for property is strong, that visibility becomes even more valuable.

It is a business that sits at the heart of real estate activity and digital advertising, and I think that combination gives it a unique ability to grow over time without needing to constantly reinvent itself.

Sigma Healthcare Ltd (ASX: SIG)

Sigma Healthcare is another ASX share I'd look at buying with the $5,000.

Following its merger with Chemist Warehouse, the business now sits across both distribution and retail, which creates a more integrated model than it had in the past.

What I find compelling is how that changes its position in the supply chain. Instead of being one step removed, the company is now more directly connected to the end customer. That can create efficiencies, improve margins, and open up new opportunities over time.

It is still early days for this combined structure, but I think the long-term potential lies in how those two sides of the business work together.

ResMed Inc (ASX: RMD)

ResMed has had a tough run, with the share price hitting a 52-week low on Friday.

That kind of move can draw attention, but what matters more to me is what is happening within the business.

ResMed operates in sleep and respiratory care, and demand in that area is closely linked to awareness and diagnosis. As more people recognise the importance of sleep health, more patients enter the system, which can support long-term growth.

As well as devices, the company has a growing software business. It is about managing patient outcomes over time, which can create a more connected and recurring relationship with users.

In my opinion, that combination of hardware and software is what makes the business stand out.

Foolish Takeaway

If I had $5,000 to invest today, I would focus on ASX 200 shares that are building long-term momentum in different ways.

Hub24 is benefiting from structural growth in platform-based investing, REA Group continues to strengthen its position in digital property advertising, Sigma Healthcare is evolving into a more integrated healthcare business, and ResMed is building a broader ecosystem around sleep and respiratory care.

I think they offer a mix of growth drivers that could play out over time and deliver attractive returns.

The post If I had $5,000 to invest in ASX 200 shares today, here's what I'd buy appeared first on The Motley Fool Australia.

For me, simplicity usually comes down to choosing businesses that are easy to understand, operate in essential areas, and have relatively predictable earnings.

That does not remove risk, but it can make it easier to stay invested and build confidence over time.

Here are three ASX shares I think are straightforward starting points.

Woolworths Group Ltd (ASX: WOW)

Woolworths is about as easy as it gets to understand.

It sells groceries and everyday essentials, which means it benefits from consistent demand. People still need to buy food regardless of what the economy is doing.

What I like here is the stability. The business generates steady cash flow, which supports regular dividends and ongoing investment in its operations.

There is also a gradual growth element through improvements in efficiency, supply chain, and digital capabilities.

For someone starting out, I think that mix of simplicity and reliability can be helpful.

Telstra Group Ltd (ASX: TLS)

Telstra offers exposure to another essential service.

Telecommunications infrastructure underpins how people work, communicate, and consume content. That creates a recurring revenue base for the company.

What stands out to me is the predictability. Telstra has a large customer base and generates consistent earnings, which helps support its dividend payments.

It may not be a high-growth business, but I think it can play a steady role over time, particularly for investors interested in income.

Sigma Healthcare Ltd (ASX: SIG)

Finally, Sigma Healthcare adds a slightly different angle.

Following its merger with Chemist Warehouse, the business now has a much larger presence across both distribution and retail pharmacy.

I think that integration is important. It gives Sigma Healthcare exposure to the full supply chain, from wholesaling medicines to selling them directly to consumers around the world.

Healthcare demand also tends to be relatively stable, supported by long-term trends such as population growth and ageing.

For someone starting out, I think Sigma offers a combination of defensiveness and growth potential, even if the share price may move around in the short term.

Foolish takeaway

Starting to invest does not require complex strategies. For me, it is about choosing businesses you can understand and hold with confidence.

Woolworths, Telstra, and Sigma Healthcare operate in areas people rely on every day, which supports steady demand.

I think that kind of foundation can make it easier to stay focused on the long term and continue building from there.

The post 3 simple ASX shares to start investing today appeared first on The Motley Fool Australia.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Guzman Y Gomez Ltd (ASX: GYG)

According to a note out of Morgans, its analysts have retained their buy rating on this burrito seller's shares with an improved price target of $26.70. Morgans was pleased with the company's third-quarter update last week. It highlights that Guzman Y Gomez delivered a meaningful acceleration in Australian comparable store sales growth. It believes this provides tangible evidence that the business is executing well against a challenging consumer backdrop. In addition, Morgans points out that transaction growth continued to outpace comparable store sales growth. This maintains the company's growth strategy to be volume and frequency-led rather than price-driven. The Guzman Y Gomez share price ended the week at $20.68.

Lovisa Holdings Ltd (ASX: LOV)

A note out of UBS reveals that its analysts have upgraded this fashion jewellery retailer's shares to a buy rating with a $26.00 price target. UBS points out that Lovisa's shares have fallen heavily this year. This has been driven by concerns over slower store growth, softer like-for-like sales in the Australian market, and ongoing losses from the new Jewells store brand. However, the broker believes much of this is now priced in. Furthermore, it believes the resilience of Lovisa's youth-focused, low price point offering is underappreciated by the market, and expects management to prevent sustained losses from Jewells. This will be by either fixing the business or considering a closure. The Lovisa share price was fetching $23.32 at Friday's close.

Sigma Healthcare Ltd (ASX: SIG)

Analysts at Morgans have upgraded this pharmacy chain operator and wholesale distributor's shares to a buy rating with a $3.36 price target. According to the note, the broker is forecasting Sigma to deliver strong earnings growth over the medium term. This is expected to be supported by same store sales growth, store rollouts, and synergies from the Chemist Warehouse merger. In light of this and recent share price weakness, Morgans sees now as a good time to invest. The Sigma Healthcare share price ended the week at $2.69.

The post Top brokers name 3 ASX shares to buy next week appeared first on The Motley Fool Australia.

To narrow things down, let's take a look at whether analysts rate the popular ASX shares below as buys right now. Here's what you need to know:

Life360 Inc. (ASX: 360)

Bell Potter thinks this family safety technology company could be undervalued at current levels. Last week, the broker put a buy rating and $35.50 price target on its shares.

Although Bell Potter suspects that Life360 could fall short of its monthly active user growth guidance in 2026, it hasn't made any revisions to its estimates. That's because it believes it will convert more than expected users into paid subscribers. It explains:

Despite the lowering in our global MAU growth forecast in 2026 there is no change in our revenue or earnings forecasts as, on the flip side, we have increased our conversion rate forecasts so that there is no change in our paying circle forecast for the full year. Our average forecast quarterly conversion rate – measured in crude or broad terms – has increased from 3.4% to 3.5% which is still below the average 3.6% in 2025. We are therefore still modestly below last year's level which is perhaps conservative given the addition of Pet GPS but there was an unusual spike in the conversion rate in 3Q2025 which we assume is not repeated this year.

Northern Star Resources Ltd (ASX: NST)

Bell Potter has been looking at this gold miner and sees an opportunity for investors. It has put a buy rating and $35.00 price target on its shares. The broker believes a recent share buyback signals value in the underlying business. It said:

NST announced the commencement of an on market Buy-back scheme of up to A$500m, representing ~1.6% of issued capital. The buy-back is separate from the dividend payout policy of 20-30% of cash earnings and will commence on the 23rd of April. The buy-back has minimal impact on our EPS estimates going forward, however the signalling of value in the underlying business is of more importance.

Sigma Healthcare Ltd (ASX: SIG)

Finally, Morgans has put a buy rating and $3.36 price target on this pharmacy chain operator and wholesale distributor.

It thinks investors should buy the dip after the Chemist Warehouse owner's shares pulled back recently. It explains:

SIG is a leading healthcare wholesaler, distributor and retail pharmacy franchisor with operations in Australia, NZ, Ireland and the UAE. We are forecasting ~20% EBIT growth p.a. over the next few years driven by strong LFL sales growth, store rollout (domestically and internationally), operating efficiencies and $100m p.a. synergies by FY29. Given the share price weakness, we have upgraded our recommendation to BUY (from ACCUMULATE) with an unchanged target price of $3.36 and 26% upside.

The post Buy, hold, sell: Life360, Northern Star, and Sigma shares appeared first on The Motley Fool Australia.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:

Genesis Minerals Ltd (ASX: GMD)

According to a note out of Bell Potter, its analysts have retained their buy rating and $9.90 price target on this gold miner's shares. The broker has been looking ahead to the release of its third-quarter update this month. While it is expecting a small decline in production compared to the last quarter, it is forecasting production ahead of consensus estimates. Outside this, the broker remains very positive on gold and believes Genesis Minerals would be a good way to gain exposure to it. This is especially the case given the discount its shares trade on compared to peers. The Genesis Minerals share price is trading at $6.54 this afternoon.

Goodman Group (ASX: GMG)

A note out of UBS reveals that its analysts have retained their buy rating and $33.92 price target on this industrial property company's shares. This follows news that Goodman has formed a joint venture with DataBank for its Los Angeles data centre. This will enable the launch of a new 32MW facility in the city, which is one of the most supply-constrained data centre markets in the United States. UBS is positive on the deal and believes it could generate strong profits. Overall, the broker highlights that this deal demonstrates Goodman's ability to secure partners and execute on its data centre strategy. The Goodman share price is fetching $27.89 at the time of writing.

Sigma Healthcare Ltd (ASX: SIG)

Analysts at Morgans have upgraded this pharmacy chain operator and wholesale distributor's shares to a buy rating with a $3.36 price target. According to the note, the broker believes Sigma is well-placed to deliver strong earnings growth over the medium term. This is expected to be underpinned by same store sales growth, store rollouts, and synergies from the Chemist Warehouse merger. And given recent share price weakness, it sees now as an opportune to invest. The Sigma Healthcare share price is trading at $2.72 today.

The post Brokers name 3 ASX shares to buy right now appeared first on The Motley Fool Australia.

The Sigma Healthcare share price is $2.73 on Friday, up 0.9% today but down 7.3% in the year to date (YTD).

Sigma Healthcare merged with Chemist Warehouse last year, and also owns other pharmacy chains, Amcal and Discount Drug Stores.

The blockbuster merger, completed in February 2025, sent the Sigma Healthcare share price to a multi-decade high of $3.28 by June.

The merged group now supports more than 880 franchised pharmacies and supplies more than 3,500 chemists across Australia. 

It has operations in New Zealand, Ireland, and the United Arab Emirates (UAE) as well.

Market exuberance around the deal began to wear off in the second half of last year.

The Sigma share price has fallen 17% since its peak as the broader healthcare sector also encountered multiple headwinds.

Sigma Healthcare shares touched a 15-month low of $2.58 apiece last month.

Morgans 'prescribing long term growth'

In a new note released yesterday, Morgans said ongoing share price weakness had prompted it to upgrade the ASX healthcare share.

Morgans titled its note 'prescribing long term growth' and moved its rating up from accumulate to buy.

The broker kept its 12-month share price target at $3.36.

Morgans said it is forecasting about 20% growth in earnings before interest and taxes (EBIT) over the next few years.

The broker said it expects strong like-for-like sales growth and new stores to be rolled out domestically and internationally.

It also anticipates operating efficiencies and about $100 million per annum in synergies by FY29.

The broker commented:

Given the share price weakness, we have upgraded our recommendation to BUY (from ACCUMULATE) with an unchanged target price of $3.36 and 26% upside.

Morgans previously described Sigma Healthcare's 1H FY26 report as "solid" and in line with consensus expectations.

What do other experts think?

Ord Minnett and Jefferies also upgraded Sigma Healthcare shares to a buy rating over the past few weeks.

Ord Minnett lowered its 12-month target from $3.40 to $3.30, while Jefferies has a target of $3.05.

Meanwhile, RBC Capital recently initiated coverage on the ASX healthcare share with a hold rating and a $2.50 target.

Macquarie also has a hold rating and lifted its share price target from $3 to $3.20 early last month.

Jarden also upgraded Sigma Healthcare shares to a buy rating in late February, with a $3.60 price target.

The post Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse appeared first on The Motley Fool Australia.

Two of the underperforming companies are in the technology sector, two are in healthcare, while the fifth is a major property developer.

Here's what's happening.

Two ASX 200 tech shares dropping to fresh one-year-plus lows

The first company making this rather ignominious list today is WiseTech Global Ltd (ASX: WTC).

Shares in the logistics software solutions company are down 5.1% in late morning trade today, changing hands for $36.42 each. That sees the WiseTech share price down 55.2% over 12 months and trading at its lowest level since June 2022.

WiseTech shares have come under pressure over the past months amid increasing concerns that artificial intelligence (AI) could soon be able to deliver much of the same services the company offers at materially cheaper costs.

Which brings us to the second ASX 200 share trading at 52-week-plus lows today, Xero Ltd (ASX: XRO).

Shares in the business and accounting software provider are down 4.9% at the time of writing, trading for $69.25 apiece. This puts the Xero share price down 55.3% over 12 months and trading at its lowest level since November 2022.

Like WiseTech, Xero shares are facing negative investor sentiment amid the rapid rise of AI technologies.

Two ASX 200 healthcare shares sinking to new 52-week lows

Moving on to the healthcare space, we have Sigma Healthcare Ltd (ASX: SIG).

Shares in the retail pharmacy giant, which merged with Chemist Warehouse in 2025, are down 0.6% today, trading for $2.605 each. That sees the Sigma Healthcare share price down 9.6% in a year and at its lowest level since December 2024, prior to the merger.

ResMed Inc (ASX: RMD) shares are also doing it tough.

Shares in the sleep disorder treatment company are down 1.3% today, changing hands for $31.925 each. That puts this ASX 200 share down 8.7% over 12 months and trading at its lowest level since August 2024.

As for the property development giant…

Interest rates may be biting

Stockland Corp Ltd (ASX: SGP) shares join our list of stocks slumping to new one-year-plus lows today.

Shares in the diversified property development company are down 1.4% on Monday, trading for $4.20 each. That puts this ASX 200 share down 14.3% over 12 months and trading at its lowest level since January 2025.

Like many real estate companies, Stockland shares have faced headwinds amid resurgent global inflation and expectations of higher interest rates to come. Real estate stocks tend to perform better in low and falling interest rate environments.

The post 5 ASX 200 shares including WiseTech and Xero plumbing new 52-week-plus lows on Monday appeared first on The Motley Fool Australia.

A lot has happened in the last few weeks as a result of the Middle East events, one of which is ASX share market valuations taking a hit.

When share prices fall, it's a good idea to look for opportunities that could deliver market-beating returns over the long-term. With that in mind, let's look at two of the most well-liked ASX shares by analysts.

Life360 Inc (ASX: 360)

Life360 describes itself as a family connection and safety company, keeping people close to people, pets and things they care about most, with a range of services, including location sharing, safe driver reports, and crash detection with emergency dispatch.

Impressively, the business serves approximately 95.8 million monthly active users (MAU) across more than 180 countries.

According to CMC Invest, there are currently seven buy ratings on the ASX share, with an average price target of $32.80. That implies a possible rise of around 70% over the next year.

The company is growing at a very pleasing pace – compounding is a powerful financial force.

Life360 reported that in the fourth quarter of 2025, revenue increased 26% year-over-year to $146 million, while annualised monthly revenue (AMR) rose 30% to $478 million.

Those excellent levels of growth were partly driven by the fact that total MAU grew 20% year-over-year, with global paying circles increasing 26% to 2.8 million.

The paying circle growth is being driven by both the US (with 23% growth to 2 million) and internationally (with 32% growth to 0.8 million).

The company is also increasing prices, which is helping drive the average revenue per paying circle (ARPPC) – this increased by 6% year-over-year to $139.54.

Most importantly, the revenue growth is turning into rising profit, which is the key driver of increasing the intrinsic value of a business. In the 2025 fourth quarter, adjusted operating profit (EBITDA) grew 53% to $32.4 million.

Sigma Healthcare Ltd (ASX: SIG)

The company has multiple brands – Chemist Warehouse, Amcal and Discount Drug Stores. It supports Australia's largest retail network of franchised pharmacies, with more than 880 franchised pharmacies.

According to CMC Invest, there are currently six buy ratings on the business. The average price target on the ASX share is $3.25, suggesting a possible rise of 24% over the next year.

Going forward, Chemist Warehouse will be the key earnings driver of the business due to its scale and growth plans.

In the FY26 half-year result, the company's revenue grew by 14.9% to $5.5 billion, normalised operating profit (EBIT) grew 18.7% to $582.9 million and normalised net profit jumped 19.2% to $392 million.

Those numbers were largely driven by Australian Chemist Warehouse-branded stores, with sales growth of 17.2%.

In the first half of FY26, it reached 550 Australian Chemist Warehouse stores and 97 international Chemist Warehouse stores, this represented an increase from 537 Australian locations and 86 international locations at the end of FY25. Currently, international growth is focused in New Zealand and Ireland.

Through a combination of strong comparable store sales, ongoing store network expansion in Australia and overseas, and rising profit margins, it seems the ASX share is on track for a very compelling future.

According to the forecast on CMC Invest, the Sigma Healthcare share price is valued at 29x FY28's estimated earnings.

The post 2 ASX shares highly recommended to buy: Experts appeared first on The Motley Fool Australia.

After completing its merger with Chemist Warehouse last year, the business now represents a scaled, integrated, healthcare and retail pharmacy powerhouse.

And yet, despite that transformation, the share price has pulled back sharply. At around $2.58, Sigma is sitting at a 52-week low and down more than 20% from its recent highs.

That raises an obvious question for investors. Is this a buying opportunity?

A stronger business than before

The first thing to understand is that Sigma today is not the same business it was a few years ago.

The Chemist Warehouse merger has materially changed the earnings profile. The combined group is now benefiting from strong retail sales growth, expanding store networks, and increasing scale advantages across its supply chain.

Its latest half-year result highlighted this clearly. Revenue rose 14.9% to $5.5 billion, while normalised net profit after tax increased 19.2%.

Importantly, this growth is not being driven by one-off factors. Chemist Warehouse has a long track record of strong same-store sales growth, supported by its value proposition and brand strength. That momentum appears to be continuing, with double-digit growth across both domestic and international markets.

At the same time, Sigma is progressing integration and synergy benefits, with a target of $100 million per annum in synergies by FY29.

In other words, the business is getting bigger, more efficient, and more profitable.

A defensive growth profile

One of the reasons Sigma stands out to me is its mix of defensiveness and growth.

Healthcare spending tends to be relatively resilient, even during economic slowdowns. People still need prescriptions, essential health products, and everyday pharmacy items regardless of the economic backdrop.

That provides a level of earnings stability that many other retail-exposed businesses lack.

But Sigma is not just defensive. It also has multiple growth levers. These include store network expansion, private label product growth, international rollout, and ongoing efficiency gains from scale.

I think this combination is powerful. It means investors are not just buying stability, but also a long runway for earnings growth.

Valuation is not cheap, but may be justified

Of course, there is a catch with this ASX 200 stock

Sigma is not what most investors would describe as cheap.

According to CommSec, the company is expected to generate earnings per share of 6.2 cents in FY26 and 7.1 cents in FY27. That places the stock on a relatively high price-to-earnings (P/E) multiple of approximately 42x and 36x, even after the recent share price decline.

But quality businesses often trade at a premium for a reason.

Sigma's scale, brand exposure through Chemist Warehouse, defensive earnings profile, and synergy potential arguably justify a higher valuation than a typical distributor or retailer.

I think the recent pullback may simply reflect broader market conditions or profit-taking after a strong run, rather than any deterioration in fundamentals.

Does the fall make it a no-brainer buy?

For me, the key question is whether the long-term story has changed.

Right now, there is little evidence to suggest it has. The business continues to deliver strong growth, integration is on track, and the underlying industry dynamics remain favourable.

Yes, the valuation still requires some belief in future growth. But with multiple tailwinds and a proven retail model, that belief does not seem misplaced.

Foolish Takeaway

Sigma Healthcare's share price weakness is likely to grab attention, but the fundamentals tell a different story.

This is now a scaled, defensive healthcare business with strong growth drivers, a powerful retail brand, and meaningful synergies yet to be realised. While it is not conventionally cheap, high-quality companies rarely are.

For investors willing to look beyond short-term share price movements, I think the recent pullback could be an attractive opportunity to buy a business that is stronger and has long-term potential.

The post Does this ASX 200 stock's fall make it a no-brainer buy? appeared first on The Motley Fool Australia.

While CSL's market capitalisation has halved over two years, several other sector heavyweights have also tumbled to multi-year lows.

In fact, eight of the 10 largest ASX 200 healthcare shares are trading at or close to multi-year or 52-week lows today.

Is this an opportunity to buy the highest quality companies in the ASX 200 healthcare sector on the cheap? Or a reason to steer clear?

Blackwattle Large Cap Quality Fund portfolio managers Joe Koh and Elan Miller comment:

The sector as a whole has faced multiple headwinds, including currency and tariffs for the large multinationals and labour and cost pressures for the domestic players.

With this in mind, let's look at the state of play for the healthcare sector's three biggest players, and how the brokers rate them today.

1. CSL Ltd (ASX: CSL)

The CSL share price is $141.22, down 2.2% on Friday.

CSL remains the sector's largest company by a long shot with a market capitalisation of $70.06 billion.

The blue-chip ASX 200 healthcare share has fallen 18% year to date (YTD) and 44% over the past 12 months.

The CSL share price touched an eight-year low of $133.35 last week.

Disappointing earnings results, a company restructure, and a drop in vaccination rates worldwide are among the concerns for investors.

This week, UBS reiterated its buy rating on CSL shares with a 12-month target of $235.

Meanwhile, Ord Minnett has a hold rating with a $198 target.

In a note last month, the broker said:

Cost performance has improved significantly as CSL's business restructuring plans are implemented but revenue growth is still proving hard to come by, and the CEO's exit adds a degree of difficulty to the biotech's outlook.

Despite the apparent upside on offer, Ord Minnett will need more evidence of top-line growth and margin expansion before we can become more constructive on CSL.

2. Sigma Healthcare Ltd (ASX: SIG)

The Sigma Healthcare share price is $2.60, down 1% on Friday.

Sigma Healthcare, which owns a network of chemists, has a market capitalisation of $30.24 billion.

This ASX 200 healthcare share has fallen 12% YTD and 11% over the past year.

Sigma shares slid to a 15-month low of $2.58 in earlier trading today.

The stock has gone through a correction after reaching heady levels last year due to the Chemist Warehouse merger.

The Sigma Healthcare share price reached a multi-decade high of $3.28 in June last year.

This week, Ord Minnett upgraded Sigma Healthcare shares to a buy rating but lowered its 12-month target from $3.40 to $3.30.

Jefferies has also upgraded the ASX 200 healthcare share to a buy rating with a $3.05 target.

Morgans downgraded the stock from buy to accumulate after reviewing the company's 1H FY26 report last month.

The broker said:

SIG posted a solid 1H26, which was in line with consensus.

The highlights included solid CW LFL sales growth (up 15%), revenue growth higher than cost growth by 4.5%, and synergy targets on track.

We move to an ACCUMULATE (was Buy) due to YTD share price strength.

Morgans has a 12-month target of $3.36.

3. ResMed CDI (ASX: RMD)

The ResMed share price is $32.34, down 0.5% today.

The ASX 200 healthcare share has fallen 10% YTD and 9% over the past year.

ResMed, which makes CPAP devices to treat sleep apnoea, has a market cap of $18.66 billion.

ResMed shares fell to a 20-month low of $31.77 per share on Monday.

Last month, Ord Minnett reiterated its buy rating on ResMed shares.

Due to the higher Australian dollar, the broker reduced its AUD price target from $44.56 to $43.70.

Ord Minnett explained:

ResMed is now guiding to an FY26 gross margin of 62–63%, up from 61–63% previously, and we have upgraded our own forecast to 62.4% from 64.1% as we incorporate cheaper input costs and production efficiencies into our numbers.

A mark-to-market adjustment for the stronger Australian dollar currency means our target price in AUD falls to $43.70 from $44.56 despite a rise in our EPS forecasts.‍

We maintain a strongly positive view on ResMed as strong earnings growth boosts its net cash position, which should support higher dividends and more capital management. ‍

On The Bull last week, Nathan Lodge from Securities Vault revealed a hold rating on this ASX 200 healthcare share.

Lodge said:

Structural demand drivers, including ageing populations, increasing diagnosis rates and broader awareness of sleep health, continue to support long term growth.

However, a strong share price recovery following concerns about the impact of weight loss drugs on sleep apnoea treatment appears to leave much of the near-term optimism priced into the stock.

While the company's fundamentals remain robust, the valuation reflects its market leadership and growth outlook.

Investors may prefer to retain existing positions, while awaiting further earnings expansion, or more attractive entry points.

The ResMed share price was whacked in 2023 due to the rising use of GLP-1 medicines like Ozempic and Mounjaro for obesity.

In March 2024, ResMed released in-house research showing that GLP-1 medicines were actually a tailwind, as they encouraged people to see their doctor about their weight, leading to more diagnoses of sleep apnoea and a 10% increase in CPAP device usage.

The post ASX 200 healthcare shares down 33% in a year as heavyweights hit multi-year lows appeared first on The Motley Fool Australia.

We can't say what will happen in the next few weeks. But, I think the experience after 2020 and 2022 shows that the market is probably looking for good news to recover.

With US President Trump indicating he's keen to make a deal with Iran, this could be a great time to invest in the following businesses.

Pinnacle Investment Management Group Ltd (ASX: PNI)

Pinnacle is invested in a portfolio of funds management businesses that generally have a long track record of delivering stronger returns than their benchmarks.

It's understandable that a fall in share markets has led to a 14% drop in the Pinnacle share price over the past month, given the likely painful impact on funds under management (FUM).

But, due to the cyclical nature of the share market volatility, I believe there will be a recovery down the line.

Plus, Pinnacle's affiliates have collectively experienced billions of dollars in net inflows each financial year, which is a strong tailwind for longer-term FUM growth, even if FY26 earnings are impacted. I'm hopeful the company will add to its affiliate portfolio over the coming years.

I think this sell-off is an opportune time to invest in this ASX share, given market confidence is low.

Using the forecast on Commsec, the Pinnacle share price is valued at 20x FY26's estimated earnings.

Sigma Healthcare Ltd (ASX: SIG)

Australia's growing and ageing population is a strong tailwind for businesses involved in the healthcare industry.

Sigma is the owner of Chemist Warehouse, Australia's leading chemist business, along with other companies in the chemist industry.

Impressively, Chemist Warehouse is seeing network sales growth in the mid-teens, while its international sales are growing even faster.

The business is generating strong same-store sales growth, while also expanding its store network in Australia, New Zealand and Ireland.

Growing scale can help improve the company's profit margins, as we're seeing in its financials. In HY26, it reported revenue growth of 14.9%, normalised operating profit (EBIT) growth of 18.7% to $582.9 million, and normalised net profit growth of 19.2% to $392 million.

It's a great sign when each profit line is rising faster than the one before it. Investors usually value a business based on its net profit, so Sigma is demonstrating pleasing characteristics.  

I think the business is capable of adding dozens of new Chemist Warehouses to its global network in the coming years, which should be a strong tailwind for shareholder returns.

According to Commsec, the Sigma Healthcare share price is valued at 42x FY26's estimated earnings.

L1 Group Ltd (ASX: L1G)

This is a fund manager that offers a range of investment strategies that have performed strongly for investors across ASX shares, international shares, gold, and more.

After taking over Platinum, the business has hit the ground running on the ASX. It's planning to list a gold-listed investment company (LIC) soon, and its other LICs' performances have been excellent in recent times (though past performance is not a guarantee of future performance).

In the FY26 half-year result, the company reported underlying revenue growth of 23% to $145.1 million, underlying operating profit (EBITDA) growth of 61% to $94.9 million and underlying net profit after tax (NPAT) growth of 63% to $66.3 million.

I'm a fan of how L1 invests in its funds with a contrarian mindset and a focus on businesses with lower price-to-earnings (P/E) ratios.

I expect the business will launch additional funds over time, while organic investment performance can help FUM grow naturally as well.

I think this investment outfit is one of the most impressive in Australia and is worth owning for the long term.

The post 3 ASX shares to buy for magnificent long-term growth! appeared first on The Motley Fool Australia.

Be greedy when others are fearful.

Right now, there's definitely a lot of fear in the market.

A number of high-quality ASX shares have been pushed down to 52-week lows or worse, not necessarily because their long-term outlook has changed, but because sentiment has shifted.

That doesn't guarantee anything. But it does create an environment where buying quality at a more-than-fair price becomes possible.

Here are four ASX shares I'm seriously considering adding to my portfolio at current levels.

Sigma Healthcare Ltd (ASX: SIG)

Sigma is a very different business today than it was a few years ago.

The Chemist Warehouse merger has transformed its position, giving it exposure to one of Australia's most recognisable pharmacy brands.

What I find interesting is that the market is still assessing the combined business's earnings power.

There's potential for improved margins, better scale, and stronger earnings, but that story may take time to fully play out.

With the share price under pressure, I think this is one where patience could be rewarded.

Cochlear Ltd (ASX: COH)

Cochlear isn't usually a stock you see trading at such low levels.

It's a global leader in hearing implants, backed by decades of innovation and a strong reputation in healthcare.

The long-term drivers here haven't changed. Demand for hearing solutions continues to grow, supported by ageing populations and increasing awareness. A new product launch also looks likely to underpin growth and cement its leadership position.

Short-term weakness in the share price doesn't alter that.

For me, this looks like a high-quality business that could catch the eye of Warren Buffett. 

WiseTech Global Ltd (ASX: WTC)

WiseTech has been one of the biggest fallers, with its share price down sharply over the past year.

A lot of that seems tied to concerns around artificial intelligence (AI) and how it could impact software companies.

But I see it differently. WiseTech is embedding AI into its platform to automate workflows and improve customer outcomes. That could actually strengthen its position rather than weaken it.

The business still has a global footprint, strong annual recurring revenue (ARR), and a deeply embedded logistics platform.

At current prices, I think the risk-reward is looking compelling for buyers.

Flight Centre Travel Group Ltd (ASX: FLT)

Flight Centre is another cheap ASX share I'd consider buying.

Travel demand can move with economic conditions, but it's also a business that has shown it can adapt and recover.

What I like is that the company has streamlined its operations and is now operating more efficiently than it did in the past.

If travel demand remains resilient, there could be meaningful upside from here.

It's not without risk, but after a meaningful pullback, I think it's worth considering.

Foolish takeaway

Markets don't often give you the chance to buy multiple high-quality ASX shares at low prices.

But it has done exactly that with Sigma, Cochlear, WiseTech, and Flight Centre shares.

For me, this is one of those moments where Warren Buffett's advice feels especially relevant. When quality shares are trading at prices above fair value, I think it can pay to lean in rather than step back.

The post I'm listening to Warren Buffett and loading up on cheap ASX shares appeared first on The Motley Fool Australia.

When share prices are at their cheapest, those low valuations often coincide with the market becoming afraid of something that's developing negatively like a pandemic or inflation.

As Warren Buffett once said:

Be fearful when others are greedy and greedy when others are fearful.

Below are two picks I'm optimistic about for the long-term and feeling greedy for this week.

Sigma Healthcare Ltd (ASX: SIG)

Sigma's key business is Chemist Warehouse, the leader in Australia. Most of its earnings are generated in Australia and it provides a range of essential products.

It's clear that the business is growing rapidly, with the FY26 half-year result showing pleasing growth. Total revenue rose 14.9% to $5.5 billion, normalised operating profit (EBIT) climbed 18.7% to $582.9 million and normalised net profit grew 19.2% to $392 million.

Australian Chemist Warehouse-branded store sales increased 17.2% and Sigma reported that international growth accelerated, with retail network sales growth of 24.5%. This could become a larger part of the ASX share in the coming years.

I'm expecting Sigman Healthcare to continue growing its international network – in the second half of FY26 alone it's planning to open 11 new stores, with growth concentrated in New Zealand and Ireland. There are plenty of other countries that could be appealing growth locations.

I also like that the business is growing its sales of owned and exclusive products, giving the business a stronger economic moat. Further expanding the ranges will give the business a larger total addressable market.

Its ongoing scaling should help with profit margins, while impressive mid-teen like-for-like sales at Chemist Warehouse are a strong driver of the bottom line.

According to Commsec, at the time of writing, the Sigma Healthcare share price is valued at 45x FY26's estimated earnings.

TechnologyOne Ltd (ASX: TNE)

I think TechnologyOne is one of the most defensive technology businesses on the ASX because of how it provides integral operations software to clients like governments, councils, companies, universities and so on. They need this software to operate, even if global economic growth is slowing.

The business invests heavily (around 25% of revenue each year) to develop existing and new software to be as good as it can be for subscribers. That's one of the main reasons why it expects its revenue from the existing client base to grow by at least 15% per year. At that pace, its revenue will double in size every five years.

Another reason I'm optimistic about the ASX share is that it's seeking to grow in the UK, which could be just as rewarding as the Australian market. It recently won two important councils in London, which bodes well for future wins around the UK.

Management expects its growing scale to lead to rising profit margins, a pleasing prospect when combined with growing revenue. It's aiming for $1 billion of annual recurring revenue (ARR) by FY30.

The valuation looks appealing to me, with the TechnologyOne share price trading at 54x FY26's estimated earnings (at the time of writing), according to the forecast on Commsec.

The post 2 top ASX shares I'd buy today amid falling prices appeared first on The Motley Fool Australia.

It's not often that share prices go through a decline of 10% or more. Widespread selling is painful as a shareholder but there are lower valuations (almost) across the board for brave prospective investors.

Sell-offs give us the chance to search across the S&P/ASX 300 Index (ASX: XKO) (or smaller) to find beaten-up opportunities which could then bounce back when market confidence returns.

Assuming the investment still has a positive long-term outlook, a large decline is a great opportunity to see big returns if/when there's a recovery.

For example, if a share price drops by 50%, then returning to the previous position would be a return of 100%! Of course, it's not as easy as that to find the right opportunities. I'd only go for investments I believe can deliver higher earnings in three years from now.

Where I'm seeing exciting ASX share opportunities

In my view, there are multiple areas where the market is being too bearish on certain ASX shares.

The ASX tech share (and tech-related) space is awash with names that have been hit by AI worries, then hit again by the prospect of inflation and higher interest rates. I'm thinking of names like Siteminder Ltd (ASX: SDR), TechnologyOne Ltd (ASX: TNE), Xero Ltd (ASX: XRO), REA Group Ltd (ASX: REA) and Pro Medicus Ltd (ASX: PME).

Businesses in the funds management space are certainly feeling the pain of lower share markets, as well as a hit to market confidence. I think the businesses of Pinnacle Investment Management Group Ltd (ASX: PNI), L1 Group Ltd (ASX: L1G) and Australian Ethical Investment Ltd (ASX: AEF) are very compelling options right now.

The ASX retail share space is appealing as well because market confidence in them can be cyclical. I think growing retail businesses could be particularly good long-term investments during this period, such as Temple & Webster Group Ltd (ASX: TPW), Lovisa Holdings Ltd (ASX: LOV), Universal Store Holdings Ltd (ASX: UNI) and Nick Scali Ltd (ASX: NCK).

Finally, I want to highlight some other ASX growth shares that have been caught up in the sell-off but could be generate significantly higher profit in three to five years. I'm attracted to Breville Group Ltd (ASX: BRG), Sigma Healthcare Ltd (ASX: SIG), Tuas Ltd (ASX: TUA) and Guzman Y Gomez Ltd (ASX: GYG).

The post Why buying ASX shares in March could supercharge your wealth appeared first on The Motley Fool Australia.

After yesterday's horrid 1.7% drop, investors weren't in the mood to turn the ship around today. The ASX 200 spent the entire session in the red and ended up closing down 0.82%. That leaves the index at 8,428.4 points as we head into the weekend.

This not-so-nice end to the trading week for Australian investors follows a similarly downbeat morning on the American markets.

The Dow Jones Industrial Average Index (DJX: .DJI) couldn't hold water, falling 0.44%.

The tech-heavy Nasdaq Composite Index (NASDAQ: .IXIC) only managed a slightly better performance, dropping 0.28%.

Time now to get back to the local markets and take a closer look at what was happening amongst the different ASX sectors this Friday.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

But rather than trying to chase what's hot, I prefer to focus on businesses that are executing well, growing consistently, and have clear long-term potential.

Here are four top ASX shares that stand out to me.

Sigma Healthcare Ltd (ASX: SIG)

Sigma has quietly repositioned itself over the past few years.

The key driver is its merger with Chemist Warehouse, which has created a much larger and more competitive healthcare business. That added scale should help improve efficiency, strengthen supplier relationships, and support margins over time.

It also gives Sigma exposure to one of the strongest retail pharmacy brands in Australia, which I think adds a layer of quality to the story.

For me, this is a business that may not look exciting today, but could deliver steady earnings growth as the benefits of that transformation come through.

HUB24 Ltd (ASX: HUB)

Another top ASX share I would buy is HUB24. It continues to stand out as one of the more consistent performers on the ASX.

Funds under administration keep growing, net inflows remain strong, and it continues to take share from competitors. That combination tells me the platform is resonating with advisers and clients.

There's also a broader shift toward professional financial advice and platform solutions, which provides a supportive backdrop for continued growth.

In my view, HUB24 is a high-quality compounder that is benefiting from both strong execution and favourable industry dynamics.

WiseTech Global Ltd (ASX: WTC)

WiseTech has had a tougher run recently, but I think it's still a high-quality technology business.

Its CargoWise platform plays a critical role in global logistics, and once embedded, it becomes very difficult for customers to replace. That creates sticky revenue and long-term customer relationships.

The company is also continuing to invest in product development, which should help expand its capabilities and strengthen its competitive position.

While the share price may remain volatile as AI disruption concerns linger, I see this as a business with genuine global scale and a long runway for growth.

SiteMinder Ltd (ASX: SDR)

SiteMinder is another technology company that I think deserves attention.

It provides software that helps hotels manage bookings, pricing, and distribution across multiple channels, effectively sitting at the centre of their revenue operations.

What I like is that it is now combining solid growth with improving profitability, which is an important step for any software business.

There's also a clear opportunity to deepen its relationship with customers by expanding the range of products it offers, which could support revenue growth over time.

To me, SiteMinder looks like a company that is still early in its journey, with a large addressable market and increasing momentum.

Foolish takeaway

These aren't the only ASX shares I'd consider buying right now, but they're four that stand out as top picks for different reasons.

Sigma offers a transformation story, HUB24 continues to deliver consistent growth, WiseTech has global scale, and SiteMinder is building a strong position in hotel technology.

Together, they reflect the kind of quality and growth I'd be looking for in a long-term portfolio.

The post 4 top ASX share picks to buy appeared first on The Motley Fool Australia.

Australia is a great country to do business in, but with less than 30 million people in Australia it's important to recognise there are other continents with much larger addressable markets to target.

I'm excited about the potential of the following Australian stocks. I expect both will be positions in my portfolio this year – I'm already a shareholder of the hotel software business I'm about to outline.  

Sigma Healthcare Ltd (ASX: SIG)

Sigma owns three different brands in Australia – Chemist Warehouse, Amcal and Discount Drug Stores. It's also one of the largest wholesalers in Australia. It also has Chemist Warehouse locations in New Zealand, Ireland, Dubai and China. I'm hopeful the business can expand to other international locations in the coming years.

The core Australian Chemist Warehouse (CW) business is performing strongly, with CW-branded store sales up 17.2% in the FY26 half-year result. This helped Sigma's revenue climb 14.9% to $5.5 billion, with normalised operating profit (EBIT) rising 18.7% to $582.9 million, normalised net profit increasing 19.2% to $392 million.

I was particularly pleased to see that international growth accelerated, with retail network sales increasing by 24.5% year-over-year.

Comparing its international store networks between HY26 and the end of FY25, it grew its New Zealand store network by nine to a total of 70, Ireland stores grew by three to 17 and the Dubai network was flat at two. It's expecting to open 11 stores internationally in the second half of FY26.

In China, the business is focusing on profitable online sales and plans to shut the physical store network by FY29.

With increasing operating leverage, growing store networks and an ageing and growing Australian population, there are multiple earnings tailwinds overall for the Australian stock.

According to the forecast on CMC Invest, the Sigma Healthcare share price is valued at 30x FY28's estimated earnings.

Siteminder Ltd (ASX: SDR)

Siteminder is a leading ASX tech share that provides software to thousands of hotels around the world to help them with their operations and maximise their room revenue with distribution and room pricing.

The Australian stock has built its market share over the years thanks to its offering's appeal, with the current focus being on larger hotels.

One of the most pleasing things about investing in this business today is that after falling close to 60% since October 2025, its revenue has continued growing strongly.

I like how the business has a target of revenue growth of 30% and it's working hard to generate that growth from new and existing clients, partly by offering more advanced software modules.

In the FY26 half-year result, the business grew its revenue by 25.5% to $131.1 million, while the adjusted operating profit (EBITDA) more than doubled to $12.3 million.

With growing average revenue per user (ARPU), a growing list of hotel clients and rising profit margins, this Australian stock has a very exciting future ahead, in my view.

The post 2 strong Australian stocks to buy now with $6,000 appeared first on The Motley Fool Australia.